CCXI - CCXI STOCK NEWS

ChemoCentryx announced plans to advance TAVNEOS (avacopan) into Phase III trials for treating severe hidradenitis suppurativa (HS), specifically Hurley Stage III. At the SID 2022 Annual Meeting, the company presented data showcasing the immunological profiles of HS lesions, highlighting significant inflammation in severe cases. The findings correlate with previous results from the Phase II AURORA trial, reinforcing TAVNEOS's efficacy. An FDA meeting is planned for late Q2 2022 to discuss the trial's initiation in the second half of the year.

ChemoCentryx will have its CEO, Thomas J. Schall, present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 12:30 p.m. ET in Miami, FL. The presentation will be available via a live audio webcast on the company’s website, with a replay accessible for two weeks post-event. ChemoCentryx focuses on developing therapies for inflammatory and autoimmune diseases, notably marketing TAVNEOS® for severe active ANCA-associated vasculitis and pursuing treatments for other conditions.

ChemoCentryx, Inc. (Nasdaq: CCXI) announced presentations at three major medical conferences showcasing findings from the Phase III ADVOCATE trial. This trial supported the approval of TAVNEOS^® (avacopan), an oral selective complement 5a receptor inhibitor. Key presentations include insights on respiratory tract involvement in ANCA-associated vasculitis at ATS 2022, the burden of glucocorticoid use at ISPOR 2022, and infection incidence comparison at the 59th ERA Conference. TAVNEOS is indicated for severe active ANCA-associated vasculitis; however, it does not eliminate glucocorticoid use.

ChemoCentryx reported a strong Q1 2022, with TAVNEOS® (avacopan) net sales reaching $5.4 million, a five-fold increase from Q4 2021. Key performance indicators showed significant growth: 195% increase in new Patient Start Forms, 275% in unique prescribers, and 308% in patients on the drug. The company received a $45 million milestone payment due to TAVNEOS approvals in the EU and Canada. Additionally, positive Phase I data for CCX559 demonstrates its potential as a PD-L1 inhibitor. As of March 31, 2022, ChemoCentryx had approximately $371.8 million in cash and investments.

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its first quarter 2022 financial results on May 5, 2022, after market close. An executive conference call will commence at 5:00 p.m. ET to discuss these results and address inquiries. Participants can join via phone or through a webcast available on the company's website. ChemoCentryx specializes in developing therapies for inflammatory diseases, including TAVNEOS (avacopan), an approved treatment for severe active ANCA-associated vasculitis. The company is also advancing late-stage candidates for hidradenitis suppurativa and C3 glomerulopathy.

ChemoCentryx announced initial pharmacokinetic (PK) and pharmacodynamic (PD) data for CCX559, presented at the AACR Annual Meeting 2022. The Phase I study shows promising results, with CCX559 demonstrating good oral availability and appropriate exposure levels for immune response modulation in advanced cancer patients. Key findings include increased T cell proliferation and sufficient PD-L1 target coverage, indicating potential efficacy in treating solid tumors. ChemoCentryx plans further studies and expects to advance CCX559 into Phase Ib/II trials later in 2022.

ChemoCentryx reported total revenue of $32.2 million for 2021, including $2.3 million in Q4. Following FDA approval for TAVNEOS® (avacopan) in October, it achieved $1.0 million in US net product sales in Q4 2021. The European approval of TAVNEOS in January 2022 triggered a $45 million milestone from Vifor Pharma. The company is set to initiate clinical trials for TAVNEOS in lupus nephritis and has ongoing Phase I studies for CCX559. As of December 31, 2021, ChemoCentryx had approximately $362.3 million in cash and investments.

ChemoCentryx, based in Mountain View, California, has announced that it will release its fourth quarter and full year 2021 financial results after market close on March 1, 2022. An investor conference call will follow at 5:00 p.m. Eastern Time that same day. The call will be accessible by phone and through a webcast via the Company's website. ChemoCentryx is focused on developing therapies for inflammatory and autoimmune diseases, with TAVNEOS being their key marketed product for ANCA-associated vasculitis. For further details, visit their official site.

ChemoCentryx announced that CEO Thomas J. Schall will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 5:00 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for two weeks post-event. ChemoCentryx focuses on developing therapies for inflammatory, autoimmune diseases, and cancer, and markets TAVNEOS®, an approved treatment for ANCA-associated vasculitis. For further details, please visit www.chemocentryx.com.